Author: kodiac

  • Atremorine

    Vicia faba-derived dopaminergic bioproduct with natural L-DOPA donor activity and neuroprotective properties

    A standardized biopharmaceutical extract (E-PodoFavalin-15999) obtained by non-denaturing biotechnological procedures from structural components of Vicia faba L., functioning as a potent dopaminergic enhancer, natural L-DOPA donor, and neuroprotective agent for the prevention and treatment of Parkinsonian disorders, with genotype-dependent catecholaminergic and hormonal modulation.

    Abstract

    Atremorine (E-PodoFavalin-15999) is a novel biopharmaceutical product obtained by non-denaturing biotechnological processing of structural components of Vicia faba L. (the broad bean or fava bean), developed at the EuroEspes Biomedical Research Center (now International Center of Neuroscience and Genomic Medicine, Bergondo, A Coruna, Spain) under the direction of Ramon Cacabelos for the prevention and treatment of Parkinson’s disease (PD) and related dopamine-dependent disorders. Unlike synthetic levodopa (L-DOPA) formulations, Atremorine is a complex bioproduct containing a standardized concentration of approximately 25 mg of natural L-DOPA per gram of product, together with vegetal proteins, unsaturated fatty acids, minerals, vitamins, vegetal fiber, starch, carotenoid pigments, and phytosterols, all of which are proposed to contribute synergistically to its pharmacological activity and to confer neuroprotective properties absent from purified synthetic L-DOPA.

    Preclinical studies in cell culture (human neuroblastoma SH-SY5Y cells, hippocampal slices under oxygen-glucose deprivation, striatal slices under 6-hydroxydopamine-induced neurotoxicity) and in animal models (MPTP-induced parkinsonism in mice) have demonstrated that Atremorine protects dopaminergic neurons against neurotoxic insult, inhibits microglial activation, and improves motor function [1, 2, 3]. Clinical studies in over 600 Parkinson’s disease patients have confirmed that Atremorine is a potent enhancer of catecholaminergic neurotransmission: a single 5 g oral dose produces a dramatic increase in plasma dopamine levels within one hour, with over 97 percent of patients responding [4, 5]. In drug-free PD patients, plasma dopamine levels increase from approximately 12 pg/mL to approximately 6,463 pg/mL; in patients receiving conventional antiparkinsonian therapy, dopamine levels increase from approximately 1,322 pg/mL to approximately 16,029 pg/mL, indicating substantial potentiation of conventional dopaminergic pharmacotherapy [5, 6]. The dopamine response is accompanied by significant changes in circulating catecholamines (adrenaline, noradrenaline) and in dopamine-regulated hormones (reductions in prolactin, cortisol, and growth hormone), with no significant effect on serotonin or histamine levels [4].

    The variability in the Atremorine-induced dopamine response is highly attributable to pharmacogenetic factors. Polymorphic variants in pathogenic genes (notably APOE), metabolic genes (CYP2D6, CYP2C9, CYP2C19, CYP3A4/5), and neurotransmitter transporter genes (SLC6A3/DAT, SLC6A2/NET, SLC6A4/SERT) exert genotype-dependent effects on the magnitude of the dopamine response [5, 7, 8]. APOE-3 carriers are the best responders and APOE-4 carriers are the worst; CYP2D6 normal metabolizers respond most strongly and CYP2D6 poor metabolizers respond least [5, 7]. Atremorine also exerts epigenetic activity, increasing global DNA methylation in both transgenic Alzheimer’s disease mice (3xTg model) and in PD patients, with upregulation of the de novo DNA methyltransferase DNMT3a [9]. The coadministration of Atremorine with conventional antiparkinsonian drugs allows dose reduction of the conventional agents by 25 to 50 percent, with enhancement of clinical benefits and reduction of short- and long-term adverse drug reactions [5, 6]. The compound is covered by European Patent EP3225245A1 and related filings. It is not approved by any major regulatory authority as a pharmaceutical; it is classified and distributed as a bioproduct or nutraceutical. This monograph reviews the composition, extraction, neuroprotective pharmacology, clinical dopaminergic evidence, pharmacogenomic determinants of response, handling, stack interactions, safety profile, and comparative positioning of Atremorine against five alternative dopaminergic and neuroprotective interventions for Parkinson’s disease.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1617Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Canagliflozin

    Selective sodium-glucose cotransporter 2 (SGLT2) inhibitor with secondary SGLT1 inhibitory activity

    A thiophene-containing C-glucoside developed by Mitsubishi Tanabe Pharma and licensed to Janssen as the first SGLT2 inhibitor approved in the United States, distinguished by dual SGLT2/SGLT1 inhibition and landmark cardiovascular and renal outcomes evidence from the CANVAS Program and CREDENCE trial.

    Abstract

    Canagliflozin is a potent, orally bioavailable inhibitor of the sodium-glucose cotransporter 2 (SGLT2) and the first agent of its class to receive United States Food and Drug Administration approval for the treatment of type 2 diabetes mellitus. The compound acts through an insulin-independent mechanism by blocking the reabsorption of filtered glucose in the proximal tubule of the kidney, producing sustained glycosuria, reduction in plasma glucose, modest body weight loss, and reduction in systolic blood pressure. Structurally, canagliflozin is a C-glucoside bearing a thiophene ring in the aglycone region, conferring metabolic stability against glucosidase cleavage and contributing to oral bioavailability of approximately 65 percent. The inhibition constant for human SGLT2 is approximately 4.2 nM, with approximately 160-fold to 250-fold selectivity over SGLT1 (Ki approximately 710 to 910 nM), a selectivity ratio that permits modest intestinal SGLT1 inhibition at the 300 mg clinical dose, contributing to postprandial glucose lowering through delayed intestinal glucose absorption [1, 2].

    The compound was discovered at Mitsubishi Tanabe Pharma through systematic optimization of C-glucoside scaffolds for SGLT2 potency, metabolic stability, and oral pharmacokinetics [1]. Janssen Pharmaceuticals obtained development and commercialization rights through a licensing agreement and advanced canagliflozin through a comprehensive Phase 3 program (nine controlled studies, approximately 10,285 subjects) culminating in FDA approval on 29 March 2013 under the trade name Invokana [3, 4]. The compound was subsequently approved by the European Medicines Agency in November 2013 and in multiple additional jurisdictions. A fixed-dose combination with metformin (Invokamet) was approved in 2014.

    The clinical evidence base for canagliflozin extends substantially beyond glycemic control. The CANVAS Program (Canagliflozin Cardiovascular Assessment Study and CANVAS-R; N = 10,142; mean follow-up 188.2 weeks), published by Neal et al. in the New England Journal of Medicine in 2017, demonstrated a statistically significant 14 percent reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (hazard ratio 0.86; 95 percent confidence interval 0.75 to 0.97) [5]. The CREDENCE trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; N = 4,401; median follow-up 2.62 years), published by Perkovic et al. in the New England Journal of Medicine in 2019, demonstrated a 30 percent reduction in the primary composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death (hazard ratio 0.70; 95 percent confidence interval 0.59 to 0.82), establishing canagliflozin as the first SGLT2 inhibitor with a dedicated positive renal outcomes trial [6].

    Pharmacokinetics are characterized by rapid oral absorption (time to peak 1 to 2 hours), dose-proportional exposure across a wide range (50 to 1600 mg), steady-state attainment within 4 to 5 days, and predominant elimination through hepatic O-glucuronidation by UGT1A9 and UGT2B4, producing two inactive metabolites (M5 and M7) [7]. The terminal elimination half-life is approximately 10.6 to 13.1 hours at steady state, supporting once-daily dosing. Approximately 60 percent of the administered dose is recovered in feces and 33 percent in urine. Clinically significant drug-drug interactions are limited; UGT enzyme inducers (rifampin, phenytoin, ritonavir) reduce canagliflozin exposure and may require dose adjustment.

    The safety profile includes class-related adverse events: genital mycotic infections (principally vulvovaginal candidiasis in women and balanitis in men; occurring in approximately 10 to 12 percent of patients), urinary tract infections, volume depletion events related to osmotic diuresis, and euglycemic diabetic ketoacidosis (rare but clinically significant). The CANVAS Program identified a signal for increased lower-extremity amputations (6.3 versus 3.4 per 1,000 patient-years; hazard ratio 1.97), predominantly at the toe and metatarsal level, prompting an FDA boxed warning in 2017 that was subsequently removed in 2020 after additional data, including the CREDENCE trial, did not confirm the excess risk at a comparable magnitude [5, 8]. Bone fracture risk was identified in CANVAS but not confirmed in CREDENCE. Fournier gangrene (necrotizing fasciitis of the perineum) has been reported rarely across the SGLT2 inhibitor class.

    This monograph documents the chemistry, synthesis, and structure-activity relationships of canagliflozin; the molecular pharmacology of SGLT2 and SGLT1 inhibition; the comprehensive human pharmacokinetic record; preclinical pharmacology in animal models of diabetes and kidney disease; the clinical evidence base across glycemic, cardiovascular, and renal outcomes; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; adverse-event signal including the amputation and ketoacidosis findings; and a structured comparative assessment of five SGLT2 inhibitor alternatives (dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin, and bexagliflozin) against canagliflozin on five competency standards: novelty, effect size, promising potential, side-effect profile, and overall validation.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1603Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Schisandrin B

    Dibenzocyclooctadiene lignan with pleiotropic antioxidant, hepatoprotective, anti-inflammatory, and cytoprotective activity

    A principal bioactive dibenzocyclooctadiene lignan isolated from the fruit of Schisandra chinensis, distinguished by potent Nrf2-dependent antioxidant induction, NF-kB suppression, mitochondrial protective activity, and hepatoprotective efficacy across multiple preclinical models of chemical, ischemic, and metabolic liver injury.

    Abstract

    Schisandrin B (Sch B), also designated gamma-schisandrin, is the most pharmacologically characterized dibenzocyclooctadiene lignan isolated from the dried ripe fruit of Schisandra chinensis (Turcz.) Baill., a climbing vine of the family Schisandraceae with a history of use in traditional Chinese medicine spanning more than two millennia under the name wuweizi (five-flavor berry). Among the more than 30 structurally related lignans present in the Schisandra fruit, Schisandrin B has attracted the greatest research attention owing to a convergence of potent antioxidant, anti-inflammatory, hepatoprotective, cardioprotective, and neuroprotective activities demonstrated across a substantial body of in vitro and in vivo preclinical literature. The compound acts principally through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor and its downstream antioxidant response element (ARE)-dependent gene program, producing upregulation of glutathione S-transferase, heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, superoxide dismutase, and catalase. Concurrently, Schisandrin B suppresses NF-kB nuclear translocation and downstream proinflammatory cytokine expression (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6) through inhibition of IkB-alpha degradation and suppression of MAPK cascade phosphorylation at c-Raf, MEK, ERK, JNK, and p38 nodes. Additional characterized mechanisms include enhancement of mitochondrial glutathione antioxidant status and heat shock protein induction, activation of the SIRT1/PI3K/Akt and AMPK/mTOR signaling axes, suppression of ferroptosis through upregulation of SLC7A11, GPX4, and FTH1, and modulation of pregnane X receptor (PXR)-mediated bile acid metabolism. The hepatoprotective activity is the best-validated pharmacological property: Schisandrin B protects against carbon tetrachloride-induced hepatotoxicity, D-galactosamine-induced hepatocyte apoptosis, ischemia-reperfusion liver injury, doxorubicin and pirarubicin-induced hepatotoxicity, acetaminophen hepatotoxicity, cholestatic liver injury, and metabolic-associated fatty liver disease in rodent models, with efficacy demonstrated at oral doses typically in the range of 25 to 100 mg/kg in mice and rats. The compound also exhibits preclinical cardioprotective activity against doxorubicin cardiotoxicity and angiotensin II-induced cardiac fibrosis, and neuroprotective activity against amyloid-beta-induced neuronal dysfunction, scopolamine-induced amnesia, and cisplatin-induced neurotoxicity. Pharmacokinetic characterization in rats demonstrates oral bioavailability of approximately 19 to 55 percent (with sex-dependent variation), extensive hepatic accumulation consistent with its liver-protective profile, a double-peak absorption curve suggestive of enterohepatic circulation, and linear pharmacokinetics across the 10 to 40 mg/kg oral dose range. Schisandrin B is a potent, dose-dependent, noncompetitive inhibitor of CYP3A activity (Ki approximately 16.6 mg/kg in vivo) and inhibits P-glycoprotein-mediated efflux, producing clinically relevant herb-drug interactions with CYP3A substrates including midazolam, tacrolimus, and sirolimus. The compound has not been evaluated in human clinical trials as an isolated entity; all pharmacological and safety characterization derives from preclinical studies and from clinical experience with Schisandra chinensis fruit extracts and the semi-synthetic derivative bifendate (dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate). Preclinical toxicology in dogs has demonstrated dose-dependent plasma accumulation on repeated administration, and in vitro studies at high concentrations have identified paradoxical hepatotoxicity in mouse hepatocytes and macrophages, indicating that the therapeutic window requires careful characterization before clinical translation. This monograph documents the chemistry, stereochemistry, and botanical source of Schisandrin B; the molecular pharmacology across Nrf2, NF-kB, SIRT1, AMPK, and mitochondrial mechanisms; the preclinical pharmacokinetic profile; the comprehensive preclinical evidence base across hepatoprotective, cardioprotective, neuroprotective, anti-inflammatory, and antitumor indications; sourcing and quality verification; reconstitution and handling; stack interactions with emphasis on CYP3A and P-glycoprotein; adverse events and safety signals including dose-dependent hepatotoxicity; and a comparative assessment of five related hepatoprotective or Nrf2-activating compounds against Schisandrin B on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1610Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Cebranopadol

    Mixed nociceptin/orphanin FQ peptide (NOP) receptor and opioid receptor agonist analgesic

    A first-in-class spiro-indole analgesic with near-equipotent agonism at nociceptin/orphanin FQ peptide and classical opioid receptors, developed by Grunenthal and advanced by Tris Pharma through Phase 3 acute pain trials, distinguished from conventional opioids by NOP receptor-mediated attenuation of respiratory depression and abuse liability.

    Abstract

    Cebranopadol (GRT-6005, PRK-101, TRN-228) is a first-in-class small-molecule analgesic that acts as a high-affinity agonist at the nociceptin/orphanin FQ peptide (NOP) receptor and at the three classical opioid receptor subtypes (mu, kappa, and delta), with near-equipotent activation of the NOP and mu-opioid receptors at low-nanomolar concentrations. The compound was discovered at Grunenthal GmbH in Aachen, Germany, and first described in patent literature in 2002. Scientific characterization beginning in 2013 established cebranopadol as a spiro[cyclohexane-dihydropyrano[3,4-b]indole] derivative with binding affinities (Ki) of 0.7 nM at the human mu-opioid receptor, 0.9 nM at the human NOP receptor, 2.6 nM at the kappa-opioid receptor, and 18 nM at the delta-opioid receptor, and with functional potencies (EC50) of 1.2 nM (mu), 13 nM (NOP), 17 nM (kappa), and 110 nM (delta) in calcium mobilization assays, yielding a rank order of potency mu approximately equal to NOP, then kappa, then delta. The compound acts as a full agonist at the mu-opioid and delta-opioid receptors, a near-full agonist at the NOP receptor (89 percent relative efficacy), and a partial agonist at the kappa-opioid receptor (67 percent relative efficacy). A distinctive signaling feature is G-protein bias at the NOP receptor, where cebranopadol promotes G-protein coupling without measurable beta-arrestin 2 recruitment, while retaining full beta-arrestin 2 coupling at the mu-opioid receptor.

    The dual NOP and opioid receptor agonism produces a pharmacological profile that is differentiated from conventional mu-selective opioid analgesics in three respects: (1) enhanced relative potency in models of chronic neuropathic and inflammatory pain compared with acute nociceptive pain, with a seven-fold potency advantage in the mouse formalin test relative to the tail-withdrawal paradigm; (2) attenuation of opioid-type respiratory depression, with preclinical evidence of a ceiling effect on respiratory suppression attributable to the NOP receptor contribution; and (3) reduced abuse liability, demonstrated in a Phase 1 human abuse potential study showing less drug-liking and lower subjective effects relative to hydromorphone in non-dependent recreational opioid users, and in a separate study showing less abuse potential than tramadol and oxycodone. Additionally, preclinical studies demonstrated delayed analgesic tolerance development (26 days in cebranopadol-treated animals versus 11 days for morphine at equianalgesic doses in the chronic constriction injury model).

    Pharmacokinetics in humans are characterized by complete oral absorption with approximately 40 percent bioavailability reflecting first-pass hepatic metabolism, a late time to maximum plasma concentration (4 to 6 hours), a long terminal elimination half-life of 62 to 96 hours, and an operational half-life of approximately 24 hours supporting once-daily dosing. Steady-state plasma concentrations are achieved after approximately two weeks of daily administration, with an accumulation factor of approximately 2-fold and low peak-trough fluctuation (70 to 80 percent). Clearance is influenced by CYP2C9 phenotype, with poor and intermediate metabolizers showing reduced clearance relative to extensive metabolizers. The compound does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/5 at concentrations up to 250 nM, indicating a low potential for metabolic drug-drug interactions.

    Clinical development has encompassed more than 32 clinical trials involving more than 2,200 participants. A Phase 2 randomized, double-blind, placebo-controlled and active-controlled (tapentadol) trial in chronic low back pain (Christoph et al. 2017) demonstrated statistically significant and clinically relevant analgesic efficacy at doses of 200, 400, and 600 micrograms once daily over 14 weeks. A Phase 2a trial in postoperative acute pain demonstrated efficacy at 400 and 600 microgram doses. Two pivotal Phase 3 trials (ALLEVIATE-1, in post-abdominoplasty pain, and ALLEVIATE-2, in post-bunionectomy pain) met their primary efficacy endpoints, with cebranopadol 400 micrograms demonstrating significant reduction in pain intensity versus placebo. The ALLEVIATE-2 trial additionally showed that a higher proportion of cebranopadol-treated patients required no opioid rescue medication compared with placebo. Tris Pharma, which acquired worldwide rights to cebranopadol through its 2021 acquisition of Park Therapeutics, has announced plans for FDA submission. The compound is not yet approved by any regulatory authority and is not a scheduled controlled substance as of 2025. This monograph reviews the chemistry, synthesis, dual-receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing, handling, stack interactions, safety profile, and a comparative assessment of five analgesic candidates against cebranopadol on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1597Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • TRV045

    Selective sphingosine-1-phosphate subtype 1 receptor (S1P1R) agonist with sustained signaling and absence of receptor desensitization or lymphocyte sequestration

    A selective S1P1 receptor agonist developed by Trevena as a non-opioid treatment for diabetic neuropathic pain, distinguished from fingolimod-class functional antagonists by sustained receptor activation without S1P1R desensitization, protein downregulation, or peripheral lymphocyte depletion, and with additional preclinical evidence for anti-seizure activity.

    Abstract

    TRV045 (CAS 2256030-24-5) is a novel, orally bioavailable, selective sphingosine-1-phosphate subtype 1 receptor (S1P1R) agonist under clinical development by Trevena, Inc. as a potential non-opioid treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy and, through a collaboration with the National Institutes of Health, as a potential treatment for epilepsy. The compound is distinguished from the approved S1P receptor modulator class (fingolimod, siponimod, ozanimod, ponesimod) by a pharmacological mechanism that produces sustained S1P1R agonism without the receptor internalization, functional desensitization, or S1P1R protein downregulation that characterizes fingolimod and related agents. The practical consequence of this mechanistic differentiation is the absence of peripheral lymphocyte sequestration (lymphopenia), the absence of first-dose bradycardia and atrioventricular conduction delay, and the absence of the immunosuppressive liability that defines the approved S1P modulator class and limits its application outside multiple sclerosis. In preclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy (CIPN), oral TRV045 at 1 to 10 mg/kg produced dose-dependent reversal of mechanical allodynia, cold allodynia, and thermal hyperalgesia. Effects were sustained over 14 days of repeated dosing without evidence of tolerance, receptor desensitization, or S1P1R protein reduction in spinal cord tissue. In contrast, fingolimod in the same CIPN model produced approximately 70 percent reduction in S1P1R functional activity and 30 percent protein reduction. At higher doses (100 mg/kg) in a prevention paradigm, TRV045 reduced both mechanical and cold hypersensitivity 24 hours after the final dose, with cold hypersensitivity reduction persisting seven days after treatment cessation, suggesting potential disease-modifying activity. In epilepsy models conducted through the NIH-supported Epilepsy Therapy Screening Program (ETSP), TRV045 at 30 mg/kg significantly increased time to myoclonic twitch in the pentylenetetrazol seizure threshold test and produced dose-dependent protection in the maximal electroshock seizure test with an ED50 of 18 mg/kg in rats. In human Phase 1 clinical studies, TRV045 has been evaluated in three completed trials comprising a first-in-human single and multiple ascending dose study in 89 healthy volunteers, a target engagement proof-of-concept study using the capsaicin-induced pain (PainCart) model in 25 healthy subjects, and a transcranial magnetic stimulation (TMS) and electroencephalography (EEG) proof-of-concept study in 25 healthy male subjects. The target engagement study demonstrated statistically significant, dose-dependent reduction in capsaicin-induced mechanical allodynia at 150 mg and 300 mg single doses compared to placebo. The TMS/EEG study demonstrated statistically significant increases in alpha, beta, and gamma frequency band power spectral density after four days of 250 mg daily dosing, consistent with central nervous system target engagement and modulation of cortical excitability. Across all three completed Phase 1 studies, TRV045 demonstrated a favorable tolerability profile with no serious adverse events, no drug-related discontinuations, no clinically significant lymphopenia, no bradycardia, no blood pressure changes, and no prolongation of QTcF or PR intervals. The most common adverse events were mild headache, somnolence, dizziness, and fatigue. Trevena is advancing an optimized oral formulation through clinical pharmacokinetic evaluation in preparation for Phase 2 development. TRV045 is an investigational compound not approved by the United States Food and Drug Administration. This monograph reviews the chemistry and identification of TRV045; the S1P1R agonist mechanism of action and its differentiation from functional antagonist S1P modulators; the preclinical pharmacology in neuropathic pain and epilepsy models; the Phase 1 clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interaction considerations; adverse events and safety; and a comparative assessment of five S1P receptor modulators (fingolimod, siponimod, ozanimod, ponesimod, amiselimod) against TRV045 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1599Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • DNL343

    Small molecule eukaryotic initiation factor 2B (eIF2B) activator and integrated stress response (ISR) inhibitor

    A potent, selective, CNS-penetrant bicyclo[1.1.1]pentane-centered eIF2B activator developed by Denali Therapeutics for the suppression of aberrant integrated stress response signaling in neurodegenerative disease, advanced through Phase 2/3 clinical evaluation in amyotrophic lateral sclerosis.

    Abstract

    DNL343 is a first-in-class, orally bioavailable, brain-penetrant small molecule activator of eukaryotic initiation factor 2B (eIF2B), the guanine nucleotide exchange factor that governs the rate-limiting step in translation initiation and serves as the principal regulatory node of the integrated stress response (ISR). The compound was designed at Denali Therapeutics as an improvement over the prototype tool compound ISRIB, which despite landmark demonstrations of cognitive enhancement and neuroprotection in rodent models suffered from poor aqueous solubility, limited oral bioavailability, and pharmaceutical intractability [1, 2]. DNL343 retains the symmetric bis-glycolamide pharmacophore that stabilizes the eIF2B decameric complex at the subunit interface but replaces the central cyclohexane of ISRIB with a bicyclo[1.1.1]pentane (BCP) bioisostere, conferring improved solubility, metabolic stability, and CNS penetration [3]. The compound displays an IC50 of 3.2 nanomolar in a cellular ATF4 reporter assay, a brain-to-plasma unbound concentration ratio of approximately 0.8 in rat, and a plasma elimination half-life of 31 to 46 hours in healthy human subjects, supporting once-daily oral dosing [3, 4, 5].

    Preclinically, DNL343 produced dose-dependent neuroprotection in an optic nerve crush model of acute retinal ganglion cell degeneration and, in the Eif2b5 R191H knock-in mouse model of vanishing white matter disease (a genetic ISR-driven leukoencephalopathy), restored body weight, normalized motor function, reversed ISR transcriptional signatures, normalized plasma neurofilament light chain (NfL), and extended survival from 25 percent to 84.6 percent of treated animals when administered therapeutically at advanced disease stages [1]. In inducible TDP-43 proteinopathy mouse models relevant to amyotrophic lateral sclerosis (ALS), DNL343 attenuated ISR activation and reduced markers of neurodegeneration [6].

    Clinical development proceeded through a Phase 1 trial in 95 healthy volunteers (single ascending doses of 15 to 800 mg; multiple ascending doses of 45 to 260 mg daily for 14 days), which demonstrated dose-proportional pharmacokinetics, cerebrospinal fluid (CSF) to unbound plasma ratios of 0.66 to 0.92, robust suppression of ISR biomarkers (ATF4 protein, CHAC1 transcript) in peripheral blood mononuclear cells, and a favorable tolerability profile with no serious adverse events [4, 5]. A Phase 1b study in 28 participants with ALS (100 and 200 mg daily for 28 days, followed by an 18-month open-label extension) confirmed CNS penetration with CSF-to-unbound-plasma ratios of 1.02 to 1.23, pharmacodynamic target engagement, and acceptable safety, with headache and fatigue as the most common treatment-emergent adverse events [7, 8]. The compound was subsequently advanced to Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, a 24-week randomized, placebo-controlled study enrolling 186 participants on DNL343 and 139 on placebo. In January 2025, Denali Therapeutics announced that the trial did not meet its primary endpoint of slowing disease progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) and survival, and key secondary endpoints including muscle strength and respiratory function showed no statistical separation from placebo [9, 10]. A subsequent SEC filing revealed that DNL343 did not alter NfL biomarker levels over the treatment period [10]. The compound is no longer in active clinical development for ALS.

    This monograph reviews the chemistry and design rationale of DNL343; the molecular pharmacology of eIF2B activation and ISR suppression; the comprehensive preclinical neuroprotection evidence; human pharmacokinetics across Phase 1 and Phase 1b studies; the clinical evidence base in ALS; sourcing, reconstitution, and handling considerations for research applications; stack interactions; the adverse-event profile; and a structured comparative assessment of five ISR-modulating agents (ISRIB, 2BAct, fosigotifator/ABBV-CLS-7262, IFB-088/Sephin1, and trazodone) against DNL343 on five competency standards. The compound is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from multiple chemical suppliers; investigators should confirm identity and purity on every lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1574Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • TUDCA

    Hydrophilic taurine-conjugated bile acid with chemical chaperone activity and endoplasmic reticulum stress modulation

    A taurine conjugate of ursodeoxycholic acid distinguished by chemical chaperone activity at the endoplasmic reticulum, cytoprotective modulation of the unfolded protein response, and broad preclinical neuroprotective and metabolic activity across neurodegenerative, hepatobiliary, retinal, and metabolic disease models.

    Abstract

    Tauroursodeoxycholic acid (TUDCA) is a naturally occurring hydrophilic bile acid formed by taurine conjugation of ursodeoxycholic acid (UDCA), identified in bear bile in 1902 and used in traditional Chinese medicine for centuries prior to its modern pharmacological characterization. The compound functions principally as a chemical chaperone that alleviates endoplasmic reticulum (ER) stress by stabilizing the unfolded protein response (UPR) through modulation of the three canonical ER stress sensor pathways: PERK/eIF2alpha/ATF4, IRE1alpha/XBP1, and ATF6. Beyond ER stress modulation, TUDCA exerts potent anti-apoptotic activity through prevention of Bax translocation to mitochondrial membranes, inhibition of cytochrome c release, and activation of the PI3K/Akt survival pathway. The compound stabilizes mitochondrial membrane potential, reduces reactive oxygen species production, suppresses NF-kappaB-mediated proinflammatory cytokine release, and activates the nuclear receptor FXR and the membrane receptor TGR5. TUDCA crosses the blood-brain barrier and has demonstrated neuroprotective activity in preclinical models of Alzheimer’s disease (APP/PS1 transgenic mice, reducing amyloid-beta deposition and rescuing spatial memory), Parkinson’s disease (MPTP model, preventing dopaminergic neuronal loss), Huntington’s disease (3-nitropropionic acid model, preserving striatal mitochondria), amyotrophic lateral sclerosis (SOD1 transgenic mice), retinal degeneration (multiple retinitis pigmentosa models), and ischemic stroke (reducing infarct volume by approximately 50 percent). The clinical evidence base includes Phase II trials in amyotrophic lateral sclerosis demonstrating a favorable responder rate (87 percent versus 43 percent on placebo at 1 gram twice daily for 54 weeks in the Elia 2016 trial), a randomized controlled trial in obese insulin-resistant adults demonstrating a 30 percent improvement in hepatic and muscle insulin sensitivity at 1750 mg daily for 4 weeks, multiple trials in cholestatic liver disease demonstrating 40 to 51 percent reductions in liver enzymes, a Phase I/II trial in progressive multiple sclerosis demonstrating safety and immunological biomarker effects, and the Phase II CENTAUR trial of the combination product AMX0035 (TUDCA plus sodium phenylbutyrate) in ALS, which received accelerated FDA approval in September 2022 but was withdrawn from the market in October 2024 following the failure of the confirmatory Phase III PHOENIX trial to meet primary or secondary endpoints. A separate European Phase III trial (TUDCA-ALS) of TUDCA monotherapy in 337 ALS patients similarly failed to demonstrate efficacy at 18 months. The compound has been licensed for the treatment of cholestatic liver disease and cholesterol gallstones in several European and Asian jurisdictions since 1991 and maintains a favorable safety profile, with the principal adverse events being mild gastrointestinal effects (diarrhea in approximately 14 percent, abdominal pain in approximately 6 percent). This monograph reviews the chemistry, endogenous biosynthesis, and structural pharmacology of TUDCA; the multi-target cytoprotective mechanism spanning ER stress, mitochondrial stabilization, anti-apoptosis, and anti-inflammatory pathways; the comprehensive pharmacokinetic record including hepatic first-pass metabolism and blood-brain barrier penetration; the clinical evidence base across hepatobiliary, neurodegenerative, metabolic, retinal, and inflammatory indications; the reconstitution, sourcing, and stack-interaction considerations for laboratory and research applications; and a comparative assessment of five cytoprotective and neuroprotective candidates against TUDCA on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1608Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Polygalasaponin F

    Oleanane-type triterpenoid saponin with multi-target neuroprotective, anti-inflammatory, and cognition-enhancing activity

    An oleanane triterpenoid saponin isolated from Polygala japonica Houtt. with demonstrated neuroprotection against ischemic and excitotoxic injury, long-term potentiation enhancement via NMDA receptor activation, and anti-neuroinflammatory activity through TLR4-PI3K/AKT-NF-kB and TXNIP/NLRP3 pathway modulation.

    Abstract

    Polygalasaponin F (PGSF) is an oleanane-type triterpenoid saponin originally isolated from the aerial parts of Polygala japonica Houtt., a perennial herb of the Polygalaceae family used in traditional East Asian medicine for its sedative, expectorant, and cognition-enhancing properties. The compound has a molecular formula of C53H86O23 (molecular weight 1091.2 g/mol) and bears a presqualene-derived oleanane aglycone substituted with a 3-O-beta-D-glucopyranosyl unit and a C-28 ester-linked trisaccharide chain composed of glucopyranose, rhamnopyranose, and xylopyranose residues. PGSF has emerged as a compound of substantial preclinical research interest across multiple neuroprotective and anti-inflammatory domains, supported by a growing body of in vitro and in vivo evidence published principally between 2012 and 2025.

    The pharmacological profile of PGSF is characterized by multi-target activity converging on neuronal survival, synaptic plasticity, and neuroinflammatory suppression. In adult rat hippocampal slices, PGSF at 1 to 10 micromolar induces sustained long-term potentiation (LTP) in the dentate gyrus through activation of N-methyl-D-aspartate receptors (NMDARs), with downstream phosphorylation of NR2B, calcium/calmodulin-dependent protein kinase II (CaMKII), extracellular signal-regulated kinase (ERK), and cyclic AMP response element-binding protein (CREB), placing it among a small number of natural saponins with direct electrophysiological evidence of synaptic strengthening. In cultured hippocampal neurons exposed to glutamate excitotoxicity, PGSF produces concentration-dependent neuroprotection by attenuating cytosolic calcium overload and modulating NMDAR subunit expression, specifically preserving NR2A while limiting excess NR2B-mediated calcium influx. In oxygen-glucose deprivation and reoxygenation (OGD/R) models of ischemic injury using PC12 cells and primary cortical neurons, PGSF activates the PI3K/Akt survival signaling pathway, upregulates the Bcl-2/Bax ratio, and suppresses caspase-3 activation to inhibit apoptosis.

    The anti-inflammatory pharmacology of PGSF operates through at least two characterized signaling cascades. In lipopolysaccharide-stimulated BV-2 microglial cells, PGSF suppresses tumor necrosis factor alpha (TNF-alpha) release through inhibition of the toll-like receptor 4 (TLR4) to phosphoinositide 3-kinase (PI3K) to protein kinase B (AKT) to nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling axis. In middle cerebral artery occlusion (MCAO) rat models of focal ischemia and reperfusion, PGSF ameliorates neurological deficit, reduces infarct volume, and inhibits the thioredoxin-interacting protein (TXNIP) to NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome signaling pathway. More recent studies (2024 to 2025) have identified additional mechanistic targets: PGSF downregulates the Na-K-2Cl cotransporter 1 (NKCC1) through enhanced DNA methylation, thereby reducing blood-brain barrier disruption and cerebral edema following ischemia-reperfusion, and PGSF alleviates cerebral ischemia-reperfusion injury through inhibition of excessive mitophagy, preserving mitochondrial membrane potential and reducing mitochondrial reactive oxygen species accumulation.

    No clinical trials of PGSF in humans have been conducted. The compound remains in the preclinical investigational phase, with the entirety of the evidence base derived from in vitro cell culture systems and rodent models of cerebral ischemia, glutamate excitotoxicity, and neuroinflammation. Pharmacokinetic data specific to PGSF in any species are not available in published form; general considerations for triterpenoid saponin bioavailability (gastrointestinal hydrolysis of glycosidic bonds, limited oral absorption of intact saponin, hepatic first-pass metabolism) apply and represent a translational barrier that has not been formally addressed. The compound is available from multiple research chemical suppliers at greater than 95 percent purity for in vitro and in vivo research applications. This monograph reviews the chemistry, isolation, and structural characterization of PGSF; the multi-target molecular pharmacology across NMDA receptor, PI3K/Akt, TLR4/NF-kB, TXNIP/NLRP3, NKCC1, and mitophagy pathways; the preclinical evidence base in ischemic stroke, glutamate excitotoxicity, and neuroinflammation models; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse events and safety signals from animal studies; and a comparative assessment of five neuroprotective Polygala-derived saponins against PGSF on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1615Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Hopantenic acid

    Pantoyl-GABA conjugate nootropic with GABAergic, cholinergic, and pantothenic acid-related central nervous system activity

    A synthetic homolog of pantothenic acid in which beta-alanine is replaced by gamma-aminobutyric acid, developed in the Soviet Union and Japan as a nootropic and neuroprotective agent with registered indications across pediatric and adult neurology in the Russian Federation.

    Abstract

    Hopantenic acid (homopantothenic acid, D-homopantothenic acid, N-pantoyl-GABA) is a synthetic structural analog of pantothenic acid (vitamin B5) in which the beta-alanine moiety is replaced by gamma-aminobutyric acid (GABA), producing a hybrid molecule that combines GABAergic pharmacology with pantothenate-related metabolic activity and the capacity to cross the blood-brain barrier, a property that free GABA lacks. The compound was first synthesized in the 1950s in Japan, entered clinical use as the calcium salt (calcium hopantenate) in Japan in 1978 and in the Soviet Union in 1977, and is registered in the Russian Federation under the brand names Pantogam and Pantocalcin for a broad range of neurological, psychiatric, and developmental indications in children and adults, including cognitive impairment of cerebrovascular origin, attention deficit hyperactivity disorder, perinatal encephalopathy, cerebral palsy with hyperkinetic features, epilepsy adjunctive therapy, neurogenic bladder disorders, stuttering, and tic disorders. A racemic formulation (D,L-hopantenic acid, marketed as Pantogam Active) was introduced in Russia in 2008 and exhibits enhanced anxiolytic and anticonvulsant properties attributed to the L-isomer’s interaction with GABA-A receptors and dopamine D2 receptors. The compound is not approved by the United States Food and Drug Administration, by the European Medicines Agency, or by any Western regulatory authority. The molecular pharmacology of hopantenic acid is multifaceted. At the neurotransmitter level, the compound acts as a weak agonist at the GABA-B receptor complex, with a cross-reactive potency of approximately 0.2 percent relative to GABA in radioreceptor assays, and interacts with GABA-A receptors and dopamine D2 receptors at higher concentrations. In parallel, hopantenic acid enhances high-affinity choline transport into cortical and hippocampal synaptosomes and stimulates choline acetyltransferase activity, producing a secondary cholinergic facilitation that is the principal basis for the nootropic and antidementia pharmacology characterized in preclinical studies by Nakahiro et al. (1988) and others [1, 2]. At the metabolic level, the compound is a competitive antagonist of pantothenic acid at the pantothenate kinase step of coenzyme A (CoA) biosynthesis; phosphorylation by pantothenate kinase produces phospho-hopantenic acid, which potently inhibits phosphopantothenoylcysteine synthetase and reduces cellular CoA levels [3]. This pantothenic acid antagonism is the molecular basis for the most serious reported adverse effect of the compound: a Reye-like syndrome of acute encephalopathy with hepatic steatosis, hyperammonemia, and hypoglycemia reported in multiple case series in Japan during the 1980s, principally in elderly and pediatric patients on chronic high-dose therapy, and reproduced in dogs by Noda et al. (1991) [4, 5, 6]. The encephalopathy was preventable by concurrent pantothenic acid supplementation, confirming the antagonistic mechanism. Pharmacokinetics following oral administration of the calcium salt are characterized by rapid absorption (time to peak plasma concentration approximately 1.5 hours), moderate oral bioavailability (approximately 64 percent in preclinical models), an elimination half-life of approximately 6.7 hours, and predominantly renal excretion without significant hepatic metabolism [7]. The clinical evidence base for hopantenic acid is dominated by Russian-language publications of variable methodological rigor, with the most robust trial being a multicenter, double-blind, placebo-controlled study of Pantogam in 100 children with attention deficit hyperactivity disorder, which reported statistically significant improvement on the ADHD-DSM-IV rating scale and sustained attention measures over four months at 30 mg/kg/day [8]. Additional clinical evidence supports the use of the racemic formulation (Pantogam Active) for cognitive and anxiety disorders in patients with arterial hypertension and chronic cerebral ischemia [9, 10]. This monograph reviews the chemistry, synthesis, and stereochemistry of hopantenic acid; the multifaceted mechanism of action spanning GABAergic, cholinergic, and CoA-related pathways; the pharmacokinetic profile; the clinical evidence across registered and investigational indications; the Reye-like encephalopathy safety signal and its mechanistic basis; sourcing and quality verification; reconstitution and handling; stack interactions; and a structured comparative assessment of five alternative nootropic and GABAergic compounds against hopantenic acid on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1581Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • UBX1325

    Senolytic Bcl-xL inhibitor (phosphate prodrug); small-molecule inducer of apoptosis in senescent retinal vascular endothelial cells

    A first-in-class senolytic Bcl-xL inhibitor developed by Unity Biotechnology as an intravitreal therapy for diabetic macular edema and age-related macular degeneration, distinguished from conventional anti-VEGF agents by its mechanism of selective elimination of senescent retinal vascular cells and its potential for durable, disease-modifying efficacy from infrequent dosing.

    Abstract

    UBX1325 (foselutoclax) is a soluble phosphate prodrug that is cleaved rapidly in ocular tissues by ubiquitous phosphatases to yield the active parent molecule UBX0601, a potent inhibitor of the B-cell lymphoma-extra large (Bcl-xL) anti-apoptotic protein and related Bcl-2 family members. The compound was developed by Unity Biotechnology as the first senolytic therapeutic candidate designed for intravitreal administration in ophthalmologic indications, principally diabetic macular edema (DME), diabetic retinopathy (DR), and neovascular (wet) age-related macular degeneration (AMD). The senolytic mechanism is fundamentally distinct from the anti-vascular endothelial growth factor (anti-VEGF) agents that constitute the current standard of care for these conditions: rather than neutralizing a single cytokine to reduce vascular permeability, UBX1325 selectively induces apoptosis in senescent retinal vascular endothelial cells that have accumulated in areas of disease activity, thereby removing a persistent source of pro-inflammatory and pro-permeability signaling and potentially modifying the underlying disease process rather than managing its downstream consequences.

    The compound originated from a 2016 strategic licensing arrangement between Unity Biotechnology and Ascentage Pharma, under which Unity screened Ascentage’s Bcl-2 family compound library for candidates with senolytic activity against age-related disease targets. The selected molecule, BM-962, was optimized as a phosphate prodrug (UBX1325/foselutoclax) to improve aqueous solubility for ophthalmic formulation. Preclinical studies demonstrated that intravitreal administration of UBX1325 in oxygen-induced retinopathy and streptozotocin-induced diabetic retinopathy mouse models selectively eliminated senescent cells from diseased retinal vasculature while sparing healthy tissue, reduced retinal vascular permeability, and improved retinal function as measured by electroretinography. A Phase 1 single ascending dose study in 12 patients with advanced DME and wet AMD (NCT04537884) established safety and tolerability at doses up to 10 micrograms, with no dose-limiting toxicities, no treatment-related serious adverse events, and encouraging signals of visual acuity improvement and retinal thickness reduction persisting through 12 weeks. The Phase 2 BEHOLD trial (NCT04857996) enrolled 65 patients with DME who had suboptimal response to prior anti-VEGF therapy and randomized them to a single intravitreal injection of 10 micrograms UBX1325 or sham; at 48 weeks, UBX1325-treated patients gained a mean of 6.2 ETDRS letters from baseline (5.6 letters over sham), with 53 percent of treated patients requiring no anti-VEGF rescue through the full study duration compared to 22 percent in the sham arm. These results, published in Nature Medicine in 2024, represent the first clinical demonstration of senolytic therapy in ophthalmology. The Phase 2 ENVISION trial (NCT05275205) in wet AMD did not meet its primary non-inferiority endpoint versus aflibercept at 24 weeks, though 40 percent of UBX1325-treated patients required no anti-VEGF rescue through 48 weeks. The Phase 2b ASPIRE trial (NCT06011798) evaluated repeat dosing of UBX1325 every 8 weeks versus aflibercept every 8 weeks in 52 DME patients; at 36 weeks, UBX1325 produced mean gains of 5.5 ETDRS letters, achieving non-inferiority to aflibercept at most time points except the pre-specified primary endpoint (average of weeks 20 and 24), with superior performance in a pre-specified subgroup of patients with baseline central subfield thickness below 400 microns.

    This monograph reviews the chemistry, prodrug design, and molecular pharmacology of UBX1325; the senolytic mechanism of action through Bcl-xL inhibition; the preclinical pharmacology in retinal disease models; the complete clinical evidence base across Phase 1, BEHOLD, ENVISION, and ASPIRE trials; reconstitution and handling considerations for intravitreal formulation; stack interactions with anti-VEGF agents and corticosteroids; the adverse-event and safety profile; and a structured comparative assessment of five alternative approaches to DME therapy (aflibercept, faricimab, ranibizumab, navitoclax, and dasatinib plus quercetin) against UBX1325 on five competency standards. The compound is not approved by any regulatory authority as of the monograph revision date. Unity Biotechnology is advancing development toward registrational trials.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1600Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.